Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-1,99
KB0,90
PKN65,1165,142,13
Msft420,44420,47-0,23
Nokia3,29053,2965-1,02
IBM190,86190,890,04
Mercedes-Benz Group AG73,8573,870,39
PFE27,9727,980,67
28.03.2024 19:33:50
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 19:33:26
Dyne Therapeutcs Rg (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
28,51 0,04 0,01 498 413
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.03.2024
Popis společnosti
Obecné informace
Název společnostiDyne Therapeutics Inc
TickerDYN
Kmenové akcie:Ordinary Shares
RICDYN.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 29.02.2024 141
Akcie v oběhu k 29.02.2024 81 958 068
MěnaUSD
Kontaktní informace
Ulice1560 Trapelo Road
MěstoWALTHAM
PSČ02451
ZeměUnited States
Kontatní osobaAmy Reilly
Funkce kontaktní osobySenior Vice President - Corporate Communications and Investor Relations
Telefon17 817 868 230
Fax17817868866

Business Summary: Dyne Therapeutics Inc. is a muscle disease company. The Company is focused on advancing therapeutics for patients with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that it has designed to target the genetic basis of the disease. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. The Company also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Dyne Therapeutics Inc revenues was not reported. Net loss increased 40% to $235.9M. Higher net loss reflects Research and de increase of 49% to $159.9M (expense), Labor & Related Expenses in R&D increase of 43% to $39.3M (expense), Stock-based Compensation in R&D increase of 41% to $11.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.23 to -$3.95.
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 28.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorJoshua Brumm45
Chief Operating OfficerSusanna High55
Senior Vice President - Business DevelopmentJonathan McNeill38
Senior Vice President, Head of Finance and AdministrationRichard Scalzo37
Chief Scientific OfficerOxana Beskrovnaya6202.06.2021
Chief Medical OfficerWildon Farwell48